TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03504982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189)
Description: A : 2.5 mg vericiguat A\*: 2.5 mg vericiguat B : 5 mg vericiguat C : 10 mg vericiguat C\*: 10 mg vericiguat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189)
Description: A : 2.5 mg vericiguat A\*: 2.5 mg vericiguat B : 5 mg vericiguat C : 10 mg vericiguat C\*: 10 mg vericiguat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: D: 400 mg moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: D: 400 mg moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A : vericiguat placebo 10 mg A\*: vericiguat placebo 10 mg + moxifloxacin placebo B : vericiguat placebo 10 mg C : vericiguat placebo 2.5 mg C\*: vericiguat placebo 2.5 mg + moxifloxacin placebo D : vericiguat placebo 2.5 mg + vericiguat placebo 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A : vericiguat placebo 10 mg A\*: vericiguat placebo 10 mg + moxifloxacin placebo B : vericiguat placebo 10 mg C : vericiguat placebo 2.5 mg C\*: vericiguat placebo 2.5 mg + moxifloxacin placebo D : vericiguat placebo 2.5 mg + vericiguat placebo 10 mg
Study: NCT04963140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized self-management of asthma
Description: Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) if an increased risk of asthma exacerbations is detected by the home monitoring device

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional self-management of asthma
Description: Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) is based on subject's self-perception of symptoms
Study: NCT01762956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscles training
Description: The supervised muscle training will be conducted once a week with 45 minutes each session during the RT (12 weeks). In addition to the supervised sessions, patients will be instructed about the practice of home exercises and receive a guidance booklet of exercises with explanations of each exercise to be performed. These exercises must be performed daily and should be written down in the worksheet when they are performed. After this 3 month period, the patients will be encouraged to continue the exercise protocol at home without supervision. They must attend monthly to monitor adherence to home exercises.
Study: NCT04650412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundle of comorbidities care
Description: Pulmonary function tests, blood gas analysis, transthoracic echocardiography, sleep study after stabilization of patient's index clinical condition, thus 1 month after hospital discharge
Study: NCT02289690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered by intravenous infusion on Day 1 of each 21-day cycle over approximately 30 minutes at a target area under the curve (AUC) 5 mg/mL\*minute.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered by intravenous infusion on Day 1 of each 21-day cycle over approximately 30 minutes at a target area under the curve (AUC) 5 mg/mL\*minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered by intravenous infusion on Day 1 of each 21-day cycle over approximately 30 minutes at a target area under the curve (AUC) 5 mg/mL\*minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered by intravenous infusion on Day 1 of each 21-day cycle over approximately 30 minutes at a target area under the curve (AUC) 5 mg/mL\*minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administered by intravenous infusion on Days 1 to 3 of every 21-day cycle over approximately 60 minutes at 100 mg/m².

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Administered by intravenous infusion on Days 1 to 3 of every 21-day cycle over approximately 60 minutes at 100 mg/m².

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administered by intravenous infusion on Days 1 to 3 of every 21-day cycle over approximately 60 minutes at 100 mg/m².

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administered by intravenous infusion on Days 1 to 3 of every 21-day cycle over approximately 60 minutes at 100 mg/m².

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to veliparib administered orally twice a day according to the dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to veliparib administered orally twice a day according to the dosing schedule.
Study: NCT03764137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [89Zr]Panitumumab PET-MRI
Description: All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.
Study: NCT01074866

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurally Adjusted Ventilatory Assist
Description: Non invasive ventilation under Neurally adjusted Ventilatory Assist
Study: NCT00408655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study: NCT04416464

Intervention type: OTHER
Intervention: COVID-19 Pneumonia
Description: Pneumonia due to proven or suspected SARS-Cov-2 infection
Study: NCT03686163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerve Growth Factors
Description: the experimental group patients will receive NGF 20ug/d intranasally for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks
Study: NCT03358901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YC-6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT03794414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP challenge
Description: apply PEEP 10 mmHg in one-lung ventilating patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP challenge
Description: apply PEEP 10 mmHg in one-lung ventilating patients.
Study: NCT04020679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goals of Care Initiative
Description: Can-GUIDE will provide videos on a number of SDM topics including interviews with patients and clinicians discussing patient involvement in SDM and how goal conversations can inform the decision making process. Furthermore, there will be instructional videos on how to complete the Goal conversations sheet. Accompanying the videos will be interactive elements which will help users consider the types of questions that they wish to ask their clinical teams. The goal conversation sheet allows patients to list their goals and priorities that they wish to bring up in the consultation with their clinical teams. The Goals of Care (GOC) tool is a communication aid for clinicians to summarise goals of care discussions such as those facilitated by the goals conversation sheet. The completed tool will then be logged onto the Electronic Patient Record (EPR) and is then disseminated to other HCPs involved in the patients care.
Study: NCT03113019

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy based on dendritic cells
Description: Intravenous injection of cells
Study: NCT01142700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-824393
Description: Capsule, Oral, 10 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-824393
Description: Capsule, Oral, 30 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-824393
Description: Capsule, Oral, 100 mg, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, 0 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alpha-2a
Description: Syringe, subcutaneous 180 mcg/0.5 mL, weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alpha-2a
Description: Syringe, subcutaneous 180 mcg/0.5 mL, weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alpha-2a
Description: Syringe, subcutaneous 180 mcg/0.5 mL, weekly

Intervention type: DRUG
Group type: OTHER
Intervention: Peginterferon Alpha-2a
Description: Syringe, subcutaneous 180 mcg/0.5 mL, weekly
Study: NCT04563624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: composite blocks
Description: cad cam composite blocks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceramic cad cam blocks
Description: ceramic cad cam blocks
Study: NCT01879475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 032-11
Description: Topical haemostat

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Floseal (R)
Description: Topical haemostat
Study: NCT01142700

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon Alpha-2a
Description: Syringe, subcutaneous 180 mcg/0.5 mL, weekly
Study: NCT02230787

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Recession coverage without Emdogain
Description: In the control group subjects the recession coverage surgery will be performed without Emdogain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recession coverage with Emdogain
Description: In the test group subjects the recession coverage surgery will be performed with Emdogain.
Study: NCT01142700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet, Oral, 400 or 600 mg based on weight (am) and 600 mg (pm), twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet, Oral, 400 or 600 mg based on weight (am) and 600 mg (pm), twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet, Oral, 400 or 600 mg based on weight (am) and 600 mg (pm), twice daily

Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: Tablet, Oral, 400 or 600 mg based on weight (am) and 600 mg (pm), twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Tablet, Oral, 400 or 600 mg based on weight (am) and 600 mg (pm), twice daily
Study: NCT04464343

Intervention type: OTHER
Intervention: no intervention
Description: This is an observation study, with no intervention

Intervention type: OTHER
Intervention: no intervention
Description: This is an observation study, with no intervention
Study: NCT03304574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated personalized feedback
Description: Integrated personalized feedback about self-reported risk behaviors will be generated and shown to participants as they complete their baseline health risk assessment using the CheckED Yourself app. The integrated personalized feedback is based on motivational feedback strategies such as normative feedback (comparison to peer behaviors and age-based health guidelines), increasing knowledge regarding potential consequences of behaviors, and providing practical tips for changing behavior.
Study: NCT00910312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ice-Sense
Description: Ice-Sense Cryoprobe
Study: NCT01212120

Intervention type: BIOLOGICAL
Intervention: Genetic profiling of bacterial cultures
Description: Genetic profiling of bacterial cultures harvested from both the nose and foot lesions of patients
Study: NCT03946189

Intervention type: DIAGNOSTIC_TEST
Intervention: Obtaining arterial blood gases
Description: Obtaining arterial blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: Obtaining arterial blood gases
Description: Obtaining arterial blood sample
Study: NCT00408655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study: NCT00591149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 MG/M2 IV over 2 hours on day 1 of 21 day cycle over a period of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle for a period of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks
Study: NCT01977443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APD-209 Eye drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: APD-209 Placebo Eye drops
Study: NCT05552794

Intervention type: DIAGNOSTIC_TEST
Intervention: Optic nerve Sheath Diameter (ONSD)
Description: ONSD and rSO2 monitoring will perform when the patients arrived in ICU.

Intervention type: DIAGNOSTIC_TEST
Intervention: Optic nerve Sheath Diameter (ONSD)
Description: ONSD and rSO2 monitoring will perform when the patients arrived in ICU.
Study: NCT00420940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvent 1000 Dynamic Motion Therapy (DMT) Platform
Description: Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvent 1000 Dynamic Motion Therapy (DMT) Platform
Description: Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
Study: NCT03245736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisotumab Vedotin
Description: All patients in the trial will be administered tisotumab vedotin (HuMax-TF-ADC).
Study: NCT01967121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compex unit's Active Recovery® program
Description: Compex unit's Active Recovery® program will be performed for 15 minutes once per day.

Intervention type: OTHER
Group type: OTHER
Intervention: Ice application
Description: Participants will apply ice on their hamstring for 15 minutes three times per day until muscle soreness is no longer present
Study: NCT03900078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incisional negative pressure wound therapy
Description: A negative pressure dressing is applied to the skin incision.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound dressing with adhesive tapes
Description: Regular adhesive wound tapes are applied over the closed skin.
Study: NCT03946189

Intervention type: DIAGNOSTIC_TEST
Intervention: Obtaining arterial blood gases
Description: Obtaining arterial blood sample
Study: NCT02481986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker
Description: A community health worker is para-professional who performs education, case management, and social support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Certified asthma educator
Description: A certified asthma educator has is certified and performs asthma education.
Study: NCT02630381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unfocused extracoporeal shock wave therapy
Description: Shock waves are acoustical pulses that are characterized by high amplitude (\~500 bar) and short rise time (\~20 ns), which are followed by a longer low-magnitude negative wave (\~-100 bar). Extracorporeal shock waves are widely used to disintegrate kidney stones, which is called lithotripsy. In orthopedics, shock wave therapy, called orthotripsy, is used safely in a variety of musculoskeletal disorders like non unions, osteonecrosis of the hip, Achilles and patellar tendinopathy, lateral epicondylitis of the elbow and fasciitis plantaris.~Until recently extracorporeal shock wave therapy for musculoskeletal disorders was applied with a focused character, in which the waves converge in a focal point similar to lithotripsy. For the prevention of fractures in osteoporosis a focused character is not preferable because large skeletal regions have to be treated, so unfocused shock waves have been developed.
Study: NCT04331808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 8mg/kg D1 and if no response (no decrease of oxygen requirement) a second injection at D3.
Study: NCT01557140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RASi plus carvedilol
Description: Patients were randomly assigned to 2 groups, with 1 group receiving renin-angiotensin system inhibitors (enalapril) plus carvedilol and the other receiving renin-angiotensin system inhibitors (enalapril) plus placebo
Study: NCT04084873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PBrE
Description: PbRE is a word reading task implementing through an App developed for smartphones. The patient will choose emotional positive and negative words related to personal and clinical characteristics.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: PBrE-Control
Description: Participants are exposed to several neutral words. These words do not have any emotional content and there are no reasons to think that they have any effect over the emotional regulation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Participants do not receive the intervention.
Study: NCT00735072

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
Study: NCT02186340

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Study: NCT01183104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Starting dose for sitagliptin is 50mg per day, can be increased up to 100mg (25-50mg; estimate glomerular filtration rate (eGFR) 30=\< \<50).
Study: NCT02029716

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RTA 408 Lotion 0.5%, 1%, 3%
Study: NCT01183104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Starting dose for glimepiride is 0.5mg per day, can be increased up to 6.0mg
Study: NCT02453828

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-cardiac surgery
Description: patients having non-cardiac surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-cardiac surgery
Description: patients having non-cardiac surgery
Study: NCT02986165

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: The placebo control is water containing a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose pomace extract
Description: Immediately prior to ingestion, 'drinks' containing 1 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose pomace extract
Description: Immediately prior to ingestion, 'drinks' containing 2.5 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.
Study: NCT03640104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention-Nutrition guidelines
Description: Subjects will receive an individualized dietary plan according to their nutritional status, socioeconomic and cultural preferences. Protein intake 1-1.5g/kg body weight; 30% fat (mono and polyunsaturated fatty acids), vitamin A sources (1300 RAE). Each subject will have 7 interchangeable options for every meal time, all equivalent in macronutrient content, and every two weeks a new menu will be provided by a nutritionist.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutrition guidelines
Description: Nutritional recommendations based on international guidelines
Study: NCT00231972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Enhance
Description: The behavioral intervention will be administered by a trained medical social worker on an individual basis. It will include an education component, as well as motivational and behavioral skills enhancement. Treatment will occur for only the first 3 months, after which follow-up sessions will be held every 3 months for the remainder of the year.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard prevention case management (PCM)
Description: Participants will receive standard PCM for HIV prevention.
Study: NCT02705547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Daily oral administration of Rosuvastatin (10 mg) for 3 months
Study: NCT04574791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TiZANidine 2 MG Oral Capsule
Description: Tizanidine 2 mg q8h (standing; # 42 tablets) + Multimodal pain regimen
Study: NCT06336876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Online survey launched via the Survey Monkey® portal
Study: NCT01902927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attentional distraction using IAPS protocol (standardized images)
Description: Positive, Negative and Neutral Attentional distraction will be presented using IAPS protocol (standardized images) during exercise tests
Study: NCT04211740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OCH-NCNP1
Description: OCH-NCNP1 3mg is supplied as granules and take orally once a week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as granules and take orally once a week.
Study: NCT04030819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: schema therapy
Description: The intervention is the schema therapy focuses on the management of anxiety and is based on self-efficacy, self-management . It consists of 20 once-weekly sessions of 90 minutes (with a 15 Min break), with homework activities between the sessions